Patients
From January 1st, 2010 to December 31st, 2018, a total of 46 patients
aged over 3 years were diagnosed with high risk MB. The median age at
diagnosis was 10.6 (range, 5-21) years. There were 33 male and 13 female
patients. For biological analyses, 34 (73.9%) of the 46 MB patients
were included in molecular analyses. In total, 32 patients received
intrathecal MTX and were classified in MTX group, whereas the remaining
14 were treated without intrathecal MTX and were in control group. For
the 32 patients in MTX group, 27 (84.38%) had metastatic disease, 3
(9.38%) had diffuse anaplasia, and 3 (9.38%) had residual disease
greater than 1.5 cm2. Molecular subgroup
classification was available in 28 (87.5%) patients, which assigned
patients to WNT (n=0), SHH (n=5), group 3 (n=6), and group 4 (n=17)
subgroups.
Among the 14 patients in control group, 8 (57.14%) had metastatic
disease, 3 (27.27%) had diffuse anaplasia, and 6 (42.86%) had residual
disease greater than 1.5 cm2. Molecular subgroup
classification was available in 6 (42.86%) patients, assigning patients
to WNT (n=0), SHH (n=2), group 3 (n=1), and group 4 (n=3) subgroups.
The details of these patients are presented in Supplementary Table 1.